NCT03301688View on ClinicalTrials.gov

The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

September 18, 2017

Primary Completion Date

September 15, 2018

Study Completion Date

December 15, 2019

Conditions
NSCLC
Interventions
BIOLOGICAL

Toripalimab

To compare the different drug batch number with different process

Trial Locations (1)

100021

Cancer Hospital Chinese Academy of Medical Science, Beijing

All Listed Sponsors
lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER

NCT03301688 - The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001 | Biotech Hunter | Biotech Hunter